SAGE Therapeutics (SAGE) – Hot Comments
-
Sage, Biogen receive setback despite FDA approval of postpartum depression drug. This is why
-
UPDATE: Sage Therapeutics (SAGE) PT Lowered to $60 at Mizuho Securities on Disappointing Waterfall Data
-
-
-
-
-
-
-
-
-
-
-
-
Back to SAGE Stock Lookup